Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Cancer
|
Cardiovascular
|
Infection
|
Metabolic
|
Musculoskeletal
|
CNS
|
Respiratory
|
Gastrointestinal
|
Other
|
Therapy Sector - Musculoskeletal
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK Promote your vacancy here
FDA panels vote against Jazz bid to sell sodium oxybate for fibromyalgia
23 August 2010
A joint meeting on 20 August of two US FDA advisory committees put major roadblocks in the way of Jazz Pharmaceuticals' new drug application (NDA) to sell sodium oxybate as a treatment for fibromyalgia. The panel of outside experts on arthritis ...
FDA advisors back limited expansion of Cymbalta's pain indications
20 August 2010
Proceedings of the 19 August meeting of the US FDA's advisory committee on anaesthetic drugs suggest that Lilly will get the nod to market its blockbuster drug Cymbalta (duloxetine HCl) for a new pain management indication – but that it won't be ...
Regenerative Sciences fights FDA charge that its stem cell-based procedure should be classed as a "drug"
13 August 2010
The US FDA is seeking to permanently enjoin Regenerative Sciences, a Colorado-based company, from using a cultured cell product as part of a stem cell procedure known as Regenexx to treat patients with acute orthopaedic ailments (aimed at avoiding ...
Pfizer forced to discontinue more trials for novel pain drug tanezumab
20 July 2010
Pfizer is facing further disappointment with its promising first-in-class nerve growth factor (NGF) inhibitor, tanezumab. It has been forced by the US FDA to suspend clinical trials of the agent in chronic low back pain and painful diabetic ...
Abatacept and teriparatide recommended for approval in Japan
02 July 2010
Bristol-Myers Squibb 's Orencia (abatacept) and Lilly 's Forteo (teriparatide) have been recommended for approval in Japan, for the treatment of rheumatoid arthritis (RA) and osteoporosis, respectively. The positive opinion for Orencia follows a ...
 
2010 Scrip 100 - Mixed fortunes on the R&D front
23 August 2010
Continued problems with anti-obesity drugs, more measures designed to improve R&D efficiency, and the approval of first-in-class therapeutics such as Amgen's Prolia and Dendreon's Provenge: the first ...
Payer demand for genetic tests shakes up pharma's selling practices
10 June 2010
As pharmacy benefit managers and insurers begin not only paying for pre-prescription genotyping but actively promoting it, personalised medicine in the US may get a shot in the arm. Daniel B ...
Gene therapy: a technology whose time has come?
16 April 2010
It is now almost 20 years since the first patient was enrolled into an officially sanctioned gene therapy study, and in that time the field has been through a series of successes and setbacks. Today, ...
 
GW high on pipeline of cannabis extracts
23 August 2010
GW Pharma has enjoyed recent success with its cannabinoid extract product Sativex (nabiximols), which is now approved in the UK and Spain as an add-on therapy for spasticity in multiple sclerosis, ...
Face-to-face: The FDA, Amgen, and its blockbuster biologic, denosumab
15 June 2009
In escaping the sweltering heat of America's south, Scrip's US reporter Christopher Spillane meets Amgen's chief medical officer, Dr Sean Harper , who coolly explains how the firm plans to negotiate ...
 
An alternative topical treatment of osteoarthritis of the knee with cutaneous diclofenac solution
01 July 2008
Background: Osteoarthritis (OA) is the most common chronic degenerative disease, which is characterised by the destruction of the articular cartilage and subchondral bone. The current treatment of OA ...
Emerging drugs for rheumatoid arthritis
01 March 2008
Background: Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic, autoimmune disease characterized by symmetric arthritis of diarhthrodial joints leading to progressive erosion of cartilage ...
Role of mesenchymal stem cells in regenerative medicine: application to bone and cartilage repair
01 March 2008
Background: Mesenchymal stem cells (MSC) are multipotent cells with the ability to differentiate into mesenchyme-derived cells including osteoblasts and chondrocytes. Objective: To provide an ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm